Lung Cancer

Atezolizumab shows OS benefit over chemo in PD-L1 high NSCLC

Atezolizumab could be a promising first line treatment option for patients with squamous or non-squamous non-small cell lung cancer with high PD-L1 expression, interim OS analysis from the IMpower110 trial suggests. Presenting data here at the ESMO 2019 congress, Dr David R. Spigel from the Sarah Cannon Research Institute, Nashville, Tennessee, USA, told delegates that ...

Already a member?

Login to keep reading.

© 2022 the limbic